Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Urology Cancer Center, PC

2 abstracts

Abstract
Primary analysis of STARTAR: A phase 2 salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP).
Org: University of Texas Southwestern Medical Center, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Duke University Cancer Institute, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Wake Forest Baptist Health,
Abstract
Phase 1/2a study of PRL-02, a long-acting intramuscular (IM) depot injection of abiraterone decanoate, in patients (pts) with advanced prostate cancer.
Org: Carolina Urologic Research Center, Oncology Hematology Consultants Ltd., First Urology, Urology Cancer Center, PC, National Cancer Institute, Vilnius, Lithuania,